Review



human brn2 sirna  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology human brn2 sirna
    ( A ) GSEA plots of transmembrane RTK-related gene sets enriched in PlexinD1-knockdown vs. control 22Rv1 cells, and PLXND1 -high vs. -low PCa patient samples in TCGA cohort. ( B ) Representative images of a RTK phosphorylation antibody array and quantification of p-ErbB3 levels in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 2 technical replicates). The raw values from measurement of p-ErbB3 spot intensity after background subtraction are presented. ( C ) Western blot of p-ErbB3, p-ErbB2, p-cMet, p-ERK, p-AKT, and their total protein forms in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells. ( D ) qPCR of ErbB3 ( NRG1 and NRG2 ) and cMet ( HGF ) ligand mRNA levels in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( E ) Representative PLA images and quantification of PlexinD1-ErbB3/cMet interaction by per-cell cytoplasmic fluorescence intensity in C4-2B ENZR cells treated with recombinant Sema3E/Sema3C proteins (200–500 ng/ml, 4 h) or SEMA3E / SEMA3C <t>siRNA</t> (10 μM, 48 h). PlexinD1 antibody incubation alone served as negative controls. The n of each group indicates the number of cells examined for quantification. Scale bars: 5 μm. ( F ) Co-IP assays of PlexinD1-ErbB3/cMet interaction in 22Rv1 cells. IgG was used in the IP step as negative control. Five percent of input was blotted as positive control. ( G ) Cell proliferation assays of 22Rv1 cells pre-treated with an ErbB3 neutralizing antibody (100 ng/ml, 24 h) or SGX-523 (5 µM, 24 h) and then subjected to PLXND1 siRNA addition followed by a 5-day observation period, and control and PlexinD1-overexpressing LNCaP cells upon treatment with an ErbB3 neutralizing antibody or SGX-523 during a 5-day observation period. Data represent the fold changes of cell proliferation on day 5 relative to siRNA treatment day (day 1) for 22Rv1 cells or treatment day (day 1) for LNCaP cells ( n = 3 biological replicates), with fold changes in non-treated groups of control cells set as 1 for normalization of other groups. ( H ) qPCR of stemness, basal, and NE markers as indicated in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates). ( I ) qPCR of stemness, basal, NE, and EMT markers as indicated in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). Data information: In ( B , D , E , G , H , I ), data are presented as mean ± SEM. In ( A ), P values were determined by permutation test. In ( B , D ), P values were determined by unpaired two-tailed Student’s t -test. In ( E ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test. In ( G , H , I ), P values were determined by two-way ANOVA with Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .
    Human Brn2 Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/array+scan+vti+software/Brn-2+siRNA/pmc11822115-82-0-4
    Average 93 stars, based on 1 article reviews
    human brn2 sirna - by Bioz Stars, 2026-11
    93/100 stars

    Images

    1) Product Images from "PlexinD1 is a driver and a therapeutic target in advanced prostate cancer"

    Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer

    Journal: EMBO Molecular Medicine

    doi: 10.1038/s44321-024-00186-z

    ( A ) GSEA plots of transmembrane RTK-related gene sets enriched in PlexinD1-knockdown vs. control 22Rv1 cells, and PLXND1 -high vs. -low PCa patient samples in TCGA cohort. ( B ) Representative images of a RTK phosphorylation antibody array and quantification of p-ErbB3 levels in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 2 technical replicates). The raw values from measurement of p-ErbB3 spot intensity after background subtraction are presented. ( C ) Western blot of p-ErbB3, p-ErbB2, p-cMet, p-ERK, p-AKT, and their total protein forms in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells. ( D ) qPCR of ErbB3 ( NRG1 and NRG2 ) and cMet ( HGF ) ligand mRNA levels in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( E ) Representative PLA images and quantification of PlexinD1-ErbB3/cMet interaction by per-cell cytoplasmic fluorescence intensity in C4-2B ENZR cells treated with recombinant Sema3E/Sema3C proteins (200–500 ng/ml, 4 h) or SEMA3E / SEMA3C siRNA (10 μM, 48 h). PlexinD1 antibody incubation alone served as negative controls. The n of each group indicates the number of cells examined for quantification. Scale bars: 5 μm. ( F ) Co-IP assays of PlexinD1-ErbB3/cMet interaction in 22Rv1 cells. IgG was used in the IP step as negative control. Five percent of input was blotted as positive control. ( G ) Cell proliferation assays of 22Rv1 cells pre-treated with an ErbB3 neutralizing antibody (100 ng/ml, 24 h) or SGX-523 (5 µM, 24 h) and then subjected to PLXND1 siRNA addition followed by a 5-day observation period, and control and PlexinD1-overexpressing LNCaP cells upon treatment with an ErbB3 neutralizing antibody or SGX-523 during a 5-day observation period. Data represent the fold changes of cell proliferation on day 5 relative to siRNA treatment day (day 1) for 22Rv1 cells or treatment day (day 1) for LNCaP cells ( n = 3 biological replicates), with fold changes in non-treated groups of control cells set as 1 for normalization of other groups. ( H ) qPCR of stemness, basal, and NE markers as indicated in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates). ( I ) qPCR of stemness, basal, NE, and EMT markers as indicated in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). Data information: In ( B , D , E , G , H , I ), data are presented as mean ± SEM. In ( A ), P values were determined by permutation test. In ( B , D ), P values were determined by unpaired two-tailed Student’s t -test. In ( E ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test. In ( G , H , I ), P values were determined by two-way ANOVA with Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .
    Figure Legend Snippet: ( A ) GSEA plots of transmembrane RTK-related gene sets enriched in PlexinD1-knockdown vs. control 22Rv1 cells, and PLXND1 -high vs. -low PCa patient samples in TCGA cohort. ( B ) Representative images of a RTK phosphorylation antibody array and quantification of p-ErbB3 levels in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 2 technical replicates). The raw values from measurement of p-ErbB3 spot intensity after background subtraction are presented. ( C ) Western blot of p-ErbB3, p-ErbB2, p-cMet, p-ERK, p-AKT, and their total protein forms in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells. ( D ) qPCR of ErbB3 ( NRG1 and NRG2 ) and cMet ( HGF ) ligand mRNA levels in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( E ) Representative PLA images and quantification of PlexinD1-ErbB3/cMet interaction by per-cell cytoplasmic fluorescence intensity in C4-2B ENZR cells treated with recombinant Sema3E/Sema3C proteins (200–500 ng/ml, 4 h) or SEMA3E / SEMA3C siRNA (10 μM, 48 h). PlexinD1 antibody incubation alone served as negative controls. The n of each group indicates the number of cells examined for quantification. Scale bars: 5 μm. ( F ) Co-IP assays of PlexinD1-ErbB3/cMet interaction in 22Rv1 cells. IgG was used in the IP step as negative control. Five percent of input was blotted as positive control. ( G ) Cell proliferation assays of 22Rv1 cells pre-treated with an ErbB3 neutralizing antibody (100 ng/ml, 24 h) or SGX-523 (5 µM, 24 h) and then subjected to PLXND1 siRNA addition followed by a 5-day observation period, and control and PlexinD1-overexpressing LNCaP cells upon treatment with an ErbB3 neutralizing antibody or SGX-523 during a 5-day observation period. Data represent the fold changes of cell proliferation on day 5 relative to siRNA treatment day (day 1) for 22Rv1 cells or treatment day (day 1) for LNCaP cells ( n = 3 biological replicates), with fold changes in non-treated groups of control cells set as 1 for normalization of other groups. ( H ) qPCR of stemness, basal, and NE markers as indicated in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates). ( I ) qPCR of stemness, basal, NE, and EMT markers as indicated in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). Data information: In ( B , D , E , G , H , I ), data are presented as mean ± SEM. In ( A ), P values were determined by permutation test. In ( B , D ), P values were determined by unpaired two-tailed Student’s t -test. In ( E ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test. In ( G , H , I ), P values were determined by two-way ANOVA with Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .

    Techniques Used: Knockdown, Control, Phospho-proteomics, Ab Array, Western Blot, Fluorescence, Recombinant, Incubation, Co-Immunoprecipitation Assay, Negative Control, Positive Control, Transfection, Expressing, Two Tailed Test

    ( A ) IPA upstream regulator analysis of RNA-seq data from PlexinD1-knockdown vs. control C4-2B ENZR cells, with significantly downregulated hits shown (absolute value of z-score of ≥2, p < 0.05). ( B ) STRING analysis of Gli1 linked to multiple stemness, NE, and EMT marker and/or driver genes. ( C ) Western blot of Gli1 in control and PlexinD1-manipulated PCa cells. ( D ) Determination of Gli-Luc reporter activity in control and PlexinD1-manipulated PCa cells ( n = 3 biological replicates). ( E ) qPCR of Gli1 target genes in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 3 biologial replicates). ( F ) qPCR of Hh ligands in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( G ) Determination of Gli-Luc reporter activity in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates), and in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). ( H ) Representative images of Gli1 (red color) and α-tublin (a cytoplasm marker, green color) co-IF images and quantification of Gli1+ cells in the nuclei of control and PlexinD1-manipulated 22Rv1 and LNCaP cells under the conditions as in ( G ) ( n = 3 biological replicates). Scale bars: 10 µm. ( I ) Western blot of Gli1 in nuclear and cytoplasmic fractions of control and PlexinD1-manipulated 22Rv1 and LNCaP cells under the conditions as in ( G ). ( J ) Cell proliferation assays of control and PlexinD1-overexpressing LNCaP cells upon treatment with 10 µM cyclopamine or 5 µM GANT61 for 5 days ( n = 3 biological replicates). ( K ) Cell proliferation assays of C4-2B ENZR and 22Rv1 cells upon treatment with 10 µM cyclopamine or 5 µM GANT61 for 5 days ( n = 3 biological replicates). ( L ) qPCR of stemness, NE and EMT markers in control and PlexinD1-overexpressing LNCaP cells under treatment with GANT61 (5 µM, 24 h) ( n = 3 biological replicates). ( M ) GSEA plots of two Hh signaling-related gene sets enriched in PLXND1 -high vs. -low PCa patient samples from TCGA cohort. ( N ) Chi-square analysis of distribution of select Gli1 target gene mRNA expression (L, low; H, high) in PLXND1 -low and -high PCa patient samples from TCGA cohort. Data information: In ( D – H , J – L ), data are presented as mean ± SEM. In ( A ), P values were determined by Fisher’s exact test. In ( D – F , K ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test [for C4-2B ENZR and 22Rv1 in ( D )] and unpaired two-tailed Student’s t -test [for LNCaP in ( D )]. In ( G , H , J , L ), P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. In ( M ), P values were determined by permutation test. In ( N ), P values were determined by chi-square test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .
    Figure Legend Snippet: ( A ) IPA upstream regulator analysis of RNA-seq data from PlexinD1-knockdown vs. control C4-2B ENZR cells, with significantly downregulated hits shown (absolute value of z-score of ≥2, p < 0.05). ( B ) STRING analysis of Gli1 linked to multiple stemness, NE, and EMT marker and/or driver genes. ( C ) Western blot of Gli1 in control and PlexinD1-manipulated PCa cells. ( D ) Determination of Gli-Luc reporter activity in control and PlexinD1-manipulated PCa cells ( n = 3 biological replicates). ( E ) qPCR of Gli1 target genes in control and PlexinD1-knockdown C4-2B ENZR cells ( n = 3 biologial replicates). ( F ) qPCR of Hh ligands in control and PlexinD1-knockdown C4-2B ENZR and 22Rv1 cells ( n = 3 biological replicates). ( G ) Determination of Gli-Luc reporter activity in 22Rv1 cells receiving an ErbB3 neutralizing antibody (100 ng/ml, 24 h), SGX-523 (5 µM, 24 h), or transient transfection of ErbB3/cMet expression plasmids followed by PLXND1 siRNA treatment for another 48 h ( n = 3 biological replicates), and in control and PlexinD1-overexpressing LNCaP cells upon treatment with 100 ng/ml ErbB3 neutralizing antibody or 5 µM SGX-523 for 24 h ( n = 3 biological replicates). ( H ) Representative images of Gli1 (red color) and α-tublin (a cytoplasm marker, green color) co-IF images and quantification of Gli1+ cells in the nuclei of control and PlexinD1-manipulated 22Rv1 and LNCaP cells under the conditions as in ( G ) ( n = 3 biological replicates). Scale bars: 10 µm. ( I ) Western blot of Gli1 in nuclear and cytoplasmic fractions of control and PlexinD1-manipulated 22Rv1 and LNCaP cells under the conditions as in ( G ). ( J ) Cell proliferation assays of control and PlexinD1-overexpressing LNCaP cells upon treatment with 10 µM cyclopamine or 5 µM GANT61 for 5 days ( n = 3 biological replicates). ( K ) Cell proliferation assays of C4-2B ENZR and 22Rv1 cells upon treatment with 10 µM cyclopamine or 5 µM GANT61 for 5 days ( n = 3 biological replicates). ( L ) qPCR of stemness, NE and EMT markers in control and PlexinD1-overexpressing LNCaP cells under treatment with GANT61 (5 µM, 24 h) ( n = 3 biological replicates). ( M ) GSEA plots of two Hh signaling-related gene sets enriched in PLXND1 -high vs. -low PCa patient samples from TCGA cohort. ( N ) Chi-square analysis of distribution of select Gli1 target gene mRNA expression (L, low; H, high) in PLXND1 -low and -high PCa patient samples from TCGA cohort. Data information: In ( D – H , J – L ), data are presented as mean ± SEM. In ( A ), P values were determined by Fisher’s exact test. In ( D – F , K ), P values were determined by one-way ANOVA with Dunnett’s multiple comparisons test [for C4-2B ENZR and 22Rv1 in ( D )] and unpaired two-tailed Student’s t -test [for LNCaP in ( D )]. In ( G , H , J , L ), P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. In ( M ), P values were determined by permutation test. In ( N ), P values were determined by chi-square test. * P < 0.05, ** P < 0.01; ns, not significant. Exact P values are listed in Appendix Table . .

    Techniques Used: RNA Sequencing, Knockdown, Control, Marker, Western Blot, Activity Assay, Transfection, Expressing, Two Tailed Test

    Reagents and tools table
    Figure Legend Snippet: Reagents and tools table

    Techniques Used: Recombinant, Sequencing, Control, Transfection, Membrane, Reverse Transcription, Software, Microarray, Subcloning, shRNA, Cell Viability Assay, Viability Assay, Reporter Assay, In Situ, Enzyme-linked Immunosorbent Assay, Phospho-proteomics, Extraction, Bicinchoninic Acid Protein Assay, Magnetic Beads, Gel Extraction, Purification, Ligation, Mutagenesis, Chromatin Immunoprecipitation

    Related Articles

    Control:

    Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.
    Article Snippet: Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood.. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC).. High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes.

    Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer
    Article Snippet: Human PLXND1 siRNA pool was purchased from Horizon Discovery. .. Human SEMA3C , SEMA3E , and BRN2 siRNA pools and non-target control siRNA were purchased from Santa Cruz Biotechnology. .. R1881 was purchased from Sigma-Aldrich.



    Similar Products

    90
    Thermo Fisher array scan vti software
    Array Scan Vti Software, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/array+scan+vti+software/arrayscan+vti+software/pm26422651-95-32-33
    Average 90 stars, based on 1 article reviews
    array scan vti software - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher array scan vti software (version 5.6.1.3
    Array Scan Vti Software (Version 5.6.1.3, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/array+scan+vti+software/pmc02963340-97-17-23
    Average 90 stars, based on 1 article reviews
    array scan vti software (version 5.6.1.3 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results